Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen, LICR, Iceland Genomics Get $1.7M NCI Grant to Map Cancer Pathways

NEW YORK, Oct. 12 (GenomeWeb News) - The National Cancer Institute has awarded NimbleGen, the Ludwig Institute for Cancer Research, and Iceland Genomics a $1.7 million, 4-year grant to map regulatory pathways in cancer, NimbleGen said today.

Specifically, NimbleGen and the University of San Diego branch of the LICR will co-develop next generation chromatin immunoprecipitation (ChIP)-on-chip methodologies to map transcription factor binding sites throughout the human genome. Iceland Genomics will provide samples from its clinical cancer database to be screened for TF binding using the new methodology.

It is not the first time the three have worked together. NimbleGen and LICR worked together on ChIP-on-chip technologies within the ENCODE consortium, while Iceland Genomics helped NimbleGen open its Reykjavik-based subsidiary in that country in 2002.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.